These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


226 related items for PubMed ID: 15482371

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Marketing authorization of veterinary medicinal products in Poland.
    Sztabińska-Koncka H, Lewicki J.
    Regul Toxicol Pharmacol; 1997 Aug; 26(1 Pt 1):129-33. PubMed ID: 9339489
    [Abstract] [Full Text] [Related]

  • 5. The regulatory system in europe with special emphasis on allergen products.
    Lorenz AR, Luttkopf D, Seitz R, Vieths S.
    Int Arch Allergy Immunol; 2008 Aug; 147(4):263-75. PubMed ID: 18648190
    [Abstract] [Full Text] [Related]

  • 6. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union.
    Woodward KN.
    J Vet Pharmacol Ther; 2005 Apr; 28(2):131-47. PubMed ID: 15842304
    [Abstract] [Full Text] [Related]

  • 7. European perspectives on pediatric formulations.
    Breitkreutz J.
    Clin Ther; 2008 Nov; 30(11):2146-54. PubMed ID: 19108802
    [Abstract] [Full Text] [Related]

  • 8. Biosimilars approval process.
    Zuñiga L, Calvo B.
    Regul Toxicol Pharmacol; 2010 Apr; 56(3):374-7. PubMed ID: 19925842
    [Abstract] [Full Text] [Related]

  • 9. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M, Girardin E, Kapetanovic L, Ho K, Trouvin JH.
    Horm Res; 2008 Apr; 69(1):14-21. PubMed ID: 18059081
    [Abstract] [Full Text] [Related]

  • 10. EU borderline cosmetic products review of current regulatory status.
    Morganti P, Paglialunga S.
    Clin Dermatol; 2008 Apr; 26(4):392-7. PubMed ID: 18691521
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Human health safety evaluation of cosmetics in the EU: a legally imposed challenge to science.
    Pauwels M, Rogiers V.
    Toxicol Appl Pharmacol; 2010 Mar 01; 243(2):260-74. PubMed ID: 20006634
    [Abstract] [Full Text] [Related]

  • 13. Legal constraints in EU product labelling to mitigate the environmental risk of veterinary medicines at use.
    Montforts MH, van Rijswick HF, de Haes HA.
    Regul Toxicol Pharmacol; 2004 Dec 01; 40(3):327-35. PubMed ID: 15546687
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM.
    Regul Toxicol Pharmacol; 2009 Nov 01; 55(2):181-7. PubMed ID: 19589365
    [Abstract] [Full Text] [Related]

  • 16. European Union centralised procedure for marketing authorisation of oncology drugs: an in-depth review of its efficiency.
    Netzer T.
    Eur J Cancer; 2006 Mar 01; 42(4):446-55. PubMed ID: 16129598
    [Abstract] [Full Text] [Related]

  • 17. [Human toxicological information required for registration of plant protection products--regulation in EU].
    Strohmayer A, Surján A, Sebestyén G.
    Orv Hetil; 2004 Jun 27; 145(26):1363-5. PubMed ID: 15384745
    [Abstract] [Full Text] [Related]

  • 18. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb 27; 16(87):36-42. PubMed ID: 17323539
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.